Decoding Disability Worsening in MS: The Case for Combining CSF and Serum Biomarkers

Host: Ryan Quigley A new multicenter study highlights how serum and CSF biomarkers can refine prognostic accuracy and guide treatment strategies in multiple sclerosis (MS). ReachMD's Ryan Quigley explains key findings and provides insights on how integrating these biomarkers at diagnosis could move MS care toward more personalized and effective interventions. This topic was also discussed at the 2025 Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

Guest: Marisa McGinley, DO The multiple sclerosis (MS) treatment landscape is rapidly evolving, with novel approaches on the horizon that may transform care for progressive patients. Explore the latest phase 3 data on BTK inhibitors like tolebrutinib and gain insights into ongoing CAR T-cell and remyelination research, including the BEAT-MS trial, with Dr. Marisa McGinley, a neurologist at the Cleveland Clinic.

Guest: Marisa McGinley, DO The multiple sclerosis (MS) treatment landscape is rapidly evolving, with novel approaches on the horizon that may transform care for progressive patients. Explore the latest phase 3 data on BTK inhibitors like tolebrutinib and gain insights into ongoing CAR T-cell and remyelination research, including the BEAT-MS trial, with Dr. Marisa McGinley, a neurologist at the Cleveland Clinic.

Early symptoms of multiple sclerosis (MS) often present as clear, localized neurological changes lasting several days. However, many nonspecific complaints and common MRI findings can mimic MS, leading to misdiagnosis and unnecessary treatment. Dr. Jonathan Howard, an Associate Professor of Neurology and Psychiatry at the NYU Grossman School of Medicine and the Director of the Neurology Service at Bellevue Hospital, reviews hallmark symptom patterns, explains how to differentiate benign MRI changes from true disease, and underscores the importance of thorough history-taking, neurological exams, and targeted testing to ensure accurate diagnosis and optimal patient care.

Since 2010, the landscape of multiple sclerosis care has transformed to encompass a variety of medications, each having unique benefits, risks, and side effect profiles. Dr. Jonathan Howard discusses how to match treatment strength to disease severity and balance patient risk tolerance with evolving therapeutic options, from long-standing injectables to infusions and oral therapies. Dr. Howard is an Associate Professor of Neurology and Psychiatry at the NYU Grossman School of Medicine and the Director of the Neurology Service at Bellevue Hospital in New York.

Early symptoms of multiple sclerosis (MS) often present as clear, localized neurological changes lasting several days. However, many nonspecific complaints and common MRI findings can mimic MS, leading to misdiagnosis and unnecessary treatment. Dr. Jonathan Howard, an Associate Professor of Neurology and Psychiatry at the NYU Grossman School of Medicine and the Director of the Neurology Service at Bellevue Hospital, reviews hallmark symptom patterns, explains how to differentiate benign MRI changes from true disease, and underscores the importance of thorough history-taking, neurological exams, and targeted testing to ensure accurate diagnosis and optimal patient care.

Since 2010, the landscape of multiple sclerosis care has transformed to encompass a variety of medications, each having unique benefits, risks, and side effect profiles. Dr. Jonathan Howard discusses how to match treatment strength to disease severity and balance patient risk tolerance with evolving therapeutic options, from long-standing injectables to infusions and oral therapies. Dr. Howard is an Associate Professor of Neurology and Psychiatry at the NYU Grossman School of Medicine and the Director of the Neurology Service at Bellevue Hospital in New York.

Early symptoms of multiple sclerosis (MS) often present as clear, localized neurological changes lasting several days. However, many nonspecific complaints and common MRI findings can mimic MS, leading to misdiagnosis and unnecessary treatment. Dr. Jonathan Howard, an Associate Professor of Neurology and Psychiatry at the NYU Grossman School of Medicine and the Director of the Neurology Service at Bellevue Hospital, reviews hallmark symptom patterns, explains how to differentiate benign MRI changes from true disease, and underscores the importance of thorough history-taking, neurological exams, and targeted testing to ensure accurate diagnosis and optimal patient care.

Since 2010, the landscape of multiple sclerosis care has transformed to encompass a variety of medications, each having unique benefits, risks, and side effect profiles. Dr. Jonathan Howard discusses how to match treatment strength to disease severity and balance patient risk tolerance with evolving therapeutic options, from long-standing injectables to infusions and oral therapies. Dr. Howard is an Associate Professor of Neurology and Psychiatry at the NYU Grossman School of Medicine and the Director of the Neurology Service at Bellevue Hospital in New York.

Guest: David Gate, PhD Patients with Alzheimer's disease—especially APOE4 carriers—show distinct epigenetic immune alterations that may influence disease progression, treatment response, and side effect risk. In this episode, Dr. David Gate, an Assistant Professor of Behavioral Neurology at Northwestern University, dives into his research on this subject and explains how chromatin accessibility in proinflammatory genes and T-cell receptor changes link to neurological pathology.